Skip to main content
. 2021 Dec 27;21:1354. doi: 10.1186/s12885-021-09097-5

Fig. 1.

Fig. 1

Anti-SARS-CoV-2 RBD antibody titers of 44 patients with multiple myeloma one month after two-dose SARS-CoV-2 mRNA vaccination. Results range from <0.4 to >250 U/mL with detectable antibody defined as an anti-SARS-CoV-2 RBD antibody titer >0.79 U/mL by the manufacturer